The Potential of Digital Twins for Pediatric Rare Diseases

Rare diseases affect over 300 million people globally, with approximately 75% manifesting in childhood. Their diagnosis is often delayed and approved treatments are lacking for most of the conditions. Pediatric rare diseases research is further complicated by ethical constraints and developmental diversity across childhood. Digital Twins, virtual representations of patients built from mechanistic and AI/ML models, offer a promising solution by enabling hypothesis testing, precision diagnostics, personalized therapies, and in silico trials for pediatric rare diseases. This article discusses the potential of DT applications in advancing precision medicine for pediatric rare diseases, alongside associated regulatory perspectives, modeling strategies, uncertainty analysis, as well as data, ethical and legal challenges.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2026-03-31
DOI
https://doi.org/10.1002/psp4.70234
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Potential of Digital Twins for Pediatric Rare Diseases

Ellen M. McDonagh, Henning Hermjakob, Anurag Limdi, Evangelia Petsalaki et al.
CPT Pharmacometrics & Systems Pharmacology
Genomics and Rare Diseases
article

The Potential of Digital Twins for Pediatric Rare Diseases

Ellen M. McDonagh, Henning Hermjakob, Anurag Limdi, Evangelia Petsalaki, Rahuman S. Malik‐Sheriff
article en

Abstract

Rare diseases affect over 300 million people globally, with approximately 75% manifesting in childhood. Their diagnosis is often delayed and approved treatments are lacking for most of the conditions. Pediatric rare diseases research is further complicated by ethical constraints and developmental diversity across childhood. Digital Twins, virtual representations of patients built from mechanistic and AI/ML models, offer a promising solution by enabling hypothesis testing, precision diagnostics, personalized therapies, and in silico trials for pediatric rare diseases. This article discusses the potential of DT applications in advancing precision medicine for pediatric rare diseases, alongside associated regulatory perspectives, modeling strategies, uncertainty analysis, as well as data, ethical and legal challenges.

CPT Pharmacometrics & Systems PharmacologyVol. 15(4)
European Bioinformatics Institute (GB), Wellcome Sanger Institute (GB), University of Florida (US), Open Targets (GB), Imperial College London (GB)
Silicon Valley Community Foundation
Openalex Percentile: Top 35%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The Potential of Digital Twins for Pediatric Rare Diseases — Ellen M. McDonagh, Henning Hermjakob, et al. · CPT Pharmacometrics & Systems Pharmacology (2026) | TGRS Research Map | TGRS